X Facebook LinkedIn WhatsApp Press Releases Any 2024 2023 2022 2021 2020 2019 (-) 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2018 August 21, 2018 argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody August 9, 2018 argenx to Present at 2018 Wedbush PacGrow Healthcare Conference August 1, 2018 argenx reports second quarter business update and half-year 2018 financial results July 25, 2018 argenx to host conference call & webcast to report second quarter business update July 23, 2018 argenx announces publication of full data from Phase 1 healthy volunteer study of efgartigimod in Journal of Clinical Investigation July 16, 2018 argenx receives milestone payment from strategic collaboration with Shire June 27, 2018 argenx receives second preclinical milestone payment under its development agreement with AbbVie June 19, 2018 argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris June 13, 2018 argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation June 11, 2018 argenx to host KOL breakfast symposium on immune thrombocytopenia June 5, 2018 argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis June 4, 2018 argenx selected for BEL 20 Index Pagination First page « First Previous page ‹ Previous Page 1 Current page 2 Page 3 Page 4 Next page Next › Last page Last »